Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor

The type III deletion mutant of the epidermal growth factor receptor (EGFR) is a potential target in diagnostic and therapeutic approaches for those glioblastomas characterized by its expression. We previously raised a mouse monoclonal antibody, 3C10 (IgG2b) specifically recognizing this mutant EGFR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer science 2000-10, Vol.91 (10), p.1035-1043
Hauptverfasser: Nakayashiki, Norihisa, Yoshikawa, Kazuhiro, Nakamura, Kazuyasu, Hanai, Nobuo, Okamoto, Kenta, Okamoto, Sho, Mizuno, Masaaki, Wakabayashi, Toshihiko, Saga, Sinsuke, Yoshida, Jun, Takahashi, Toshitada
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1043
container_issue 10
container_start_page 1035
container_title Cancer science
container_volume 91
creator Nakayashiki, Norihisa
Yoshikawa, Kazuhiro
Nakamura, Kazuyasu
Hanai, Nobuo
Okamoto, Kenta
Okamoto, Sho
Mizuno, Masaaki
Wakabayashi, Toshihiko
Saga, Sinsuke
Yoshida, Jun
Takahashi, Toshitada
description The type III deletion mutant of the epidermal growth factor receptor (EGFR) is a potential target in diagnostic and therapeutic approaches for those glioblastomas characterized by its expression. We previously raised a mouse monoclonal antibody, 3C10 (IgG2b) specifically recognizing this mutant EGFR. In this study, a single‐chain variable fragment (scFv) antibody was produced. Partial determination of its N‐terminal amino acid sequence and preparation of adequate primers for variable heavy chain (VH) and variable light chain (VL) genes were performed to allow cloning by means of reverse transcriptase‐polymerase chain reaction. The genes cloned were assembled with a linker, (Gly4Ser)3, and ligated into a bacterial expression vector to express the scFv as cytoplasmic inclusion bodies. After appropriate refolding, the antibody activity of the VH‐VL scFv was examined in an enzyme‐linked immunosorbent assay. 3C10 scFv showed a selective reactivity with the mutant peptide, similarly to the parental 3C10 antibody. A mouse transfectant expressing the type III mutant EGFR and a glioblastoma with type III deletion‐mutant EGFR were positively stained by immunofluorescence. By Biacore analysis, the affinity (KA) of the parental 3C10 for the mutant peptide was 9.7x107M‐1, while that of 3C10 scFv was 2.45‐2.48x107M‐1, being approximately 4‐fold weaker. The results together suggested that the scFv antibody retained the appropriate structure to recognize a conformational epitope of the mutant receptor, similarly to the parental antibody.
doi_str_mv 10.1111/j.1349-7006.2000.tb00882.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5926257</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72363521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6315-77a875a6a7fbe794fe621f0e9c6b6280975df8179f8fc2643aabd2d4eeff2d53</originalsourceid><addsrcrecordid>eNqVktFu0zAUhiMEYmXwCsgCibsW24ntmAtQVbWj0hAIKm6tE8duXSVx5yTbytUeYc_Ik-CoVRncIHxjy-f7f_32OUnyiuAJievtdkLSTI4FxnxCMcaTrsA4z-nk9lEyOpUeJyMsCR4zzPBZ8qxttxgTgTl9mpwREi8zwUbJ9Zfgy153zjfIWwTom2vWlfl5d6834Br0HYKDojJoEWBdm6ZD06ZzhS_36KvRft24H1GAVvudQcvlEn3qO4jQfOdKE2qo0EXwN90GLUB3Pgwas4uH58kTC1VrXhz382S1mK9mH8eXny-Ws-nlWPOUsLEQkAsGHIQtjJCZNZwSi43UvOA0x1Kw0uZESJtbTXmWAhQlLTNjrKUlS8-T9wfbXV_UptQxf4BK7YKrIeyVB6f-rDRuo9b-WjFJOWUiGrw5GgR_1Zu2U7VrtakqaIzvWyVoylNGyT9BIkRGs1RG8PVf4Nb3oYmfoGgqJRNS8jxS7w6UDr5tg7GnzASrYQjUVg2dVkOn1TAE6jgE6jaKXz589W_psesPMkCrobIBGu3aE5dHY5JF6sOBunGV2f9HADWbzglOWfoLnTTRAQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399579968</pqid></control><display><type>article</type><title>Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor</title><source>MEDLINE</source><source>Wiley Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nakayashiki, Norihisa ; Yoshikawa, Kazuhiro ; Nakamura, Kazuyasu ; Hanai, Nobuo ; Okamoto, Kenta ; Okamoto, Sho ; Mizuno, Masaaki ; Wakabayashi, Toshihiko ; Saga, Sinsuke ; Yoshida, Jun ; Takahashi, Toshitada</creator><creatorcontrib>Nakayashiki, Norihisa ; Yoshikawa, Kazuhiro ; Nakamura, Kazuyasu ; Hanai, Nobuo ; Okamoto, Kenta ; Okamoto, Sho ; Mizuno, Masaaki ; Wakabayashi, Toshihiko ; Saga, Sinsuke ; Yoshida, Jun ; Takahashi, Toshitada</creatorcontrib><description>The type III deletion mutant of the epidermal growth factor receptor (EGFR) is a potential target in diagnostic and therapeutic approaches for those glioblastomas characterized by its expression. We previously raised a mouse monoclonal antibody, 3C10 (IgG2b) specifically recognizing this mutant EGFR. In this study, a single‐chain variable fragment (scFv) antibody was produced. Partial determination of its N‐terminal amino acid sequence and preparation of adequate primers for variable heavy chain (VH) and variable light chain (VL) genes were performed to allow cloning by means of reverse transcriptase‐polymerase chain reaction. The genes cloned were assembled with a linker, (Gly4Ser)3, and ligated into a bacterial expression vector to express the scFv as cytoplasmic inclusion bodies. After appropriate refolding, the antibody activity of the VH‐VL scFv was examined in an enzyme‐linked immunosorbent assay. 3C10 scFv showed a selective reactivity with the mutant peptide, similarly to the parental 3C10 antibody. A mouse transfectant expressing the type III mutant EGFR and a glioblastoma with type III deletion‐mutant EGFR were positively stained by immunofluorescence. By Biacore analysis, the affinity (KA) of the parental 3C10 for the mutant peptide was 9.7x107M‐1, while that of 3C10 scFv was 2.45‐2.48x107M‐1, being approximately 4‐fold weaker. The results together suggested that the scFv antibody retained the appropriate structure to recognize a conformational epitope of the mutant receptor, similarly to the parental antibody.</description><identifier>ISSN: 0910-5050</identifier><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>EISSN: 1876-4673</identifier><identifier>DOI: 10.1111/j.1349-7006.2000.tb00882.x</identifier><identifier>PMID: 11050475</identifier><identifier>CODEN: GANNA2</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>3T3 Cells ; Amino Acid Sequence ; Animals ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - genetics ; Antibodies, Monoclonal - immunology ; Antibody Formation ; Base Sequence ; Biological and medical sciences ; Cloning ; Cloning, Molecular ; Deletion mutant ; DNA Primers ; DNA, Complementary - analysis ; Epidermal growth factor ; Epidermal growth factor receptor ; Epidermal growth factor receptors ; Epitopes ; ErbB Receptors - genetics ; ErbB Receptors - immunology ; Gene Deletion ; Gene Expression ; Glioblastoma ; Immunofluorescence ; Immunoglobulin Fragments - chemistry ; Immunoglobulin Fragments - genetics ; Immunoglobulin Fragments - immunology ; Immunoglobulin G ; Inclusion bodies ; Medical sciences ; Mice ; Molecular Sequence Data ; Monoclonal antibodies ; Mutants ; Neurology ; Peptides ; Polymerase chain reaction ; Protein Folding ; Rapid Communication ; Recombinant Proteins - chemistry ; Recombinant Proteins - immunology ; RNA-directed DNA polymerase ; scFv ; Tumors of the nervous system. Phacomatoses ; Type III deletion mutant</subject><ispartof>Cancer science, 2000-10, Vol.91 (10), p.1035-1043</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright John Wiley &amp; Sons, Inc. Oct 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6315-77a875a6a7fbe794fe621f0e9c6b6280975df8179f8fc2643aabd2d4eeff2d53</citedby><cites>FETCH-LOGICAL-c6315-77a875a6a7fbe794fe621f0e9c6b6280975df8179f8fc2643aabd2d4eeff2d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926257/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926257/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,27924,27925,45574,45575,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=834914$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11050475$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakayashiki, Norihisa</creatorcontrib><creatorcontrib>Yoshikawa, Kazuhiro</creatorcontrib><creatorcontrib>Nakamura, Kazuyasu</creatorcontrib><creatorcontrib>Hanai, Nobuo</creatorcontrib><creatorcontrib>Okamoto, Kenta</creatorcontrib><creatorcontrib>Okamoto, Sho</creatorcontrib><creatorcontrib>Mizuno, Masaaki</creatorcontrib><creatorcontrib>Wakabayashi, Toshihiko</creatorcontrib><creatorcontrib>Saga, Sinsuke</creatorcontrib><creatorcontrib>Yoshida, Jun</creatorcontrib><creatorcontrib>Takahashi, Toshitada</creatorcontrib><title>Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor</title><title>Cancer science</title><addtitle>Jpn J Cancer Res</addtitle><description>The type III deletion mutant of the epidermal growth factor receptor (EGFR) is a potential target in diagnostic and therapeutic approaches for those glioblastomas characterized by its expression. We previously raised a mouse monoclonal antibody, 3C10 (IgG2b) specifically recognizing this mutant EGFR. In this study, a single‐chain variable fragment (scFv) antibody was produced. Partial determination of its N‐terminal amino acid sequence and preparation of adequate primers for variable heavy chain (VH) and variable light chain (VL) genes were performed to allow cloning by means of reverse transcriptase‐polymerase chain reaction. The genes cloned were assembled with a linker, (Gly4Ser)3, and ligated into a bacterial expression vector to express the scFv as cytoplasmic inclusion bodies. After appropriate refolding, the antibody activity of the VH‐VL scFv was examined in an enzyme‐linked immunosorbent assay. 3C10 scFv showed a selective reactivity with the mutant peptide, similarly to the parental 3C10 antibody. A mouse transfectant expressing the type III mutant EGFR and a glioblastoma with type III deletion‐mutant EGFR were positively stained by immunofluorescence. By Biacore analysis, the affinity (KA) of the parental 3C10 for the mutant peptide was 9.7x107M‐1, while that of 3C10 scFv was 2.45‐2.48x107M‐1, being approximately 4‐fold weaker. The results together suggested that the scFv antibody retained the appropriate structure to recognize a conformational epitope of the mutant receptor, similarly to the parental antibody.</description><subject>3T3 Cells</subject><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - genetics</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibody Formation</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Cloning</subject><subject>Cloning, Molecular</subject><subject>Deletion mutant</subject><subject>DNA Primers</subject><subject>DNA, Complementary - analysis</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptor</subject><subject>Epidermal growth factor receptors</subject><subject>Epitopes</subject><subject>ErbB Receptors - genetics</subject><subject>ErbB Receptors - immunology</subject><subject>Gene Deletion</subject><subject>Gene Expression</subject><subject>Glioblastoma</subject><subject>Immunofluorescence</subject><subject>Immunoglobulin Fragments - chemistry</subject><subject>Immunoglobulin Fragments - genetics</subject><subject>Immunoglobulin Fragments - immunology</subject><subject>Immunoglobulin G</subject><subject>Inclusion bodies</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Molecular Sequence Data</subject><subject>Monoclonal antibodies</subject><subject>Mutants</subject><subject>Neurology</subject><subject>Peptides</subject><subject>Polymerase chain reaction</subject><subject>Protein Folding</subject><subject>Rapid Communication</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - immunology</subject><subject>RNA-directed DNA polymerase</subject><subject>scFv</subject><subject>Tumors of the nervous system. Phacomatoses</subject><subject>Type III deletion mutant</subject><issn>0910-5050</issn><issn>1347-9032</issn><issn>1349-7006</issn><issn>1876-4673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVktFu0zAUhiMEYmXwCsgCibsW24ntmAtQVbWj0hAIKm6tE8duXSVx5yTbytUeYc_Ik-CoVRncIHxjy-f7f_32OUnyiuAJievtdkLSTI4FxnxCMcaTrsA4z-nk9lEyOpUeJyMsCR4zzPBZ8qxttxgTgTl9mpwREi8zwUbJ9Zfgy153zjfIWwTom2vWlfl5d6834Br0HYKDojJoEWBdm6ZD06ZzhS_36KvRft24H1GAVvudQcvlEn3qO4jQfOdKE2qo0EXwN90GLUB3Pgwas4uH58kTC1VrXhz382S1mK9mH8eXny-Ws-nlWPOUsLEQkAsGHIQtjJCZNZwSi43UvOA0x1Kw0uZESJtbTXmWAhQlLTNjrKUlS8-T9wfbXV_UptQxf4BK7YKrIeyVB6f-rDRuo9b-WjFJOWUiGrw5GgR_1Zu2U7VrtakqaIzvWyVoylNGyT9BIkRGs1RG8PVf4Nb3oYmfoGgqJRNS8jxS7w6UDr5tg7GnzASrYQjUVg2dVkOn1TAE6jgE6jaKXz589W_psesPMkCrobIBGu3aE5dHY5JF6sOBunGV2f9HADWbzglOWfoLnTTRAQ</recordid><startdate>200010</startdate><enddate>200010</enddate><creator>Nakayashiki, Norihisa</creator><creator>Yoshikawa, Kazuhiro</creator><creator>Nakamura, Kazuyasu</creator><creator>Hanai, Nobuo</creator><creator>Okamoto, Kenta</creator><creator>Okamoto, Sho</creator><creator>Mizuno, Masaaki</creator><creator>Wakabayashi, Toshihiko</creator><creator>Saga, Sinsuke</creator><creator>Yoshida, Jun</creator><creator>Takahashi, Toshitada</creator><general>Blackwell Publishing Ltd</general><general>Japanese Cancer Association</general><general>John Wiley &amp; Sons, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200010</creationdate><title>Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor</title><author>Nakayashiki, Norihisa ; Yoshikawa, Kazuhiro ; Nakamura, Kazuyasu ; Hanai, Nobuo ; Okamoto, Kenta ; Okamoto, Sho ; Mizuno, Masaaki ; Wakabayashi, Toshihiko ; Saga, Sinsuke ; Yoshida, Jun ; Takahashi, Toshitada</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6315-77a875a6a7fbe794fe621f0e9c6b6280975df8179f8fc2643aabd2d4eeff2d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>3T3 Cells</topic><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - genetics</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibody Formation</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Cloning</topic><topic>Cloning, Molecular</topic><topic>Deletion mutant</topic><topic>DNA Primers</topic><topic>DNA, Complementary - analysis</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptor</topic><topic>Epidermal growth factor receptors</topic><topic>Epitopes</topic><topic>ErbB Receptors - genetics</topic><topic>ErbB Receptors - immunology</topic><topic>Gene Deletion</topic><topic>Gene Expression</topic><topic>Glioblastoma</topic><topic>Immunofluorescence</topic><topic>Immunoglobulin Fragments - chemistry</topic><topic>Immunoglobulin Fragments - genetics</topic><topic>Immunoglobulin Fragments - immunology</topic><topic>Immunoglobulin G</topic><topic>Inclusion bodies</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Molecular Sequence Data</topic><topic>Monoclonal antibodies</topic><topic>Mutants</topic><topic>Neurology</topic><topic>Peptides</topic><topic>Polymerase chain reaction</topic><topic>Protein Folding</topic><topic>Rapid Communication</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - immunology</topic><topic>RNA-directed DNA polymerase</topic><topic>scFv</topic><topic>Tumors of the nervous system. Phacomatoses</topic><topic>Type III deletion mutant</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakayashiki, Norihisa</creatorcontrib><creatorcontrib>Yoshikawa, Kazuhiro</creatorcontrib><creatorcontrib>Nakamura, Kazuyasu</creatorcontrib><creatorcontrib>Hanai, Nobuo</creatorcontrib><creatorcontrib>Okamoto, Kenta</creatorcontrib><creatorcontrib>Okamoto, Sho</creatorcontrib><creatorcontrib>Mizuno, Masaaki</creatorcontrib><creatorcontrib>Wakabayashi, Toshihiko</creatorcontrib><creatorcontrib>Saga, Sinsuke</creatorcontrib><creatorcontrib>Yoshida, Jun</creatorcontrib><creatorcontrib>Takahashi, Toshitada</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakayashiki, Norihisa</au><au>Yoshikawa, Kazuhiro</au><au>Nakamura, Kazuyasu</au><au>Hanai, Nobuo</au><au>Okamoto, Kenta</au><au>Okamoto, Sho</au><au>Mizuno, Masaaki</au><au>Wakabayashi, Toshihiko</au><au>Saga, Sinsuke</au><au>Yoshida, Jun</au><au>Takahashi, Toshitada</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor</atitle><jtitle>Cancer science</jtitle><addtitle>Jpn J Cancer Res</addtitle><date>2000-10</date><risdate>2000</risdate><volume>91</volume><issue>10</issue><spage>1035</spage><epage>1043</epage><pages>1035-1043</pages><issn>0910-5050</issn><issn>1347-9032</issn><eissn>1349-7006</eissn><eissn>1876-4673</eissn><coden>GANNA2</coden><abstract>The type III deletion mutant of the epidermal growth factor receptor (EGFR) is a potential target in diagnostic and therapeutic approaches for those glioblastomas characterized by its expression. We previously raised a mouse monoclonal antibody, 3C10 (IgG2b) specifically recognizing this mutant EGFR. In this study, a single‐chain variable fragment (scFv) antibody was produced. Partial determination of its N‐terminal amino acid sequence and preparation of adequate primers for variable heavy chain (VH) and variable light chain (VL) genes were performed to allow cloning by means of reverse transcriptase‐polymerase chain reaction. The genes cloned were assembled with a linker, (Gly4Ser)3, and ligated into a bacterial expression vector to express the scFv as cytoplasmic inclusion bodies. After appropriate refolding, the antibody activity of the VH‐VL scFv was examined in an enzyme‐linked immunosorbent assay. 3C10 scFv showed a selective reactivity with the mutant peptide, similarly to the parental 3C10 antibody. A mouse transfectant expressing the type III mutant EGFR and a glioblastoma with type III deletion‐mutant EGFR were positively stained by immunofluorescence. By Biacore analysis, the affinity (KA) of the parental 3C10 for the mutant peptide was 9.7x107M‐1, while that of 3C10 scFv was 2.45‐2.48x107M‐1, being approximately 4‐fold weaker. The results together suggested that the scFv antibody retained the appropriate structure to recognize a conformational epitope of the mutant receptor, similarly to the parental antibody.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>11050475</pmid><doi>10.1111/j.1349-7006.2000.tb00882.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0910-5050
ispartof Cancer science, 2000-10, Vol.91 (10), p.1035-1043
issn 0910-5050
1347-9032
1349-7006
1876-4673
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5926257
source MEDLINE; Wiley Journals; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects 3T3 Cells
Amino Acid Sequence
Animals
Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - genetics
Antibodies, Monoclonal - immunology
Antibody Formation
Base Sequence
Biological and medical sciences
Cloning
Cloning, Molecular
Deletion mutant
DNA Primers
DNA, Complementary - analysis
Epidermal growth factor
Epidermal growth factor receptor
Epidermal growth factor receptors
Epitopes
ErbB Receptors - genetics
ErbB Receptors - immunology
Gene Deletion
Gene Expression
Glioblastoma
Immunofluorescence
Immunoglobulin Fragments - chemistry
Immunoglobulin Fragments - genetics
Immunoglobulin Fragments - immunology
Immunoglobulin G
Inclusion bodies
Medical sciences
Mice
Molecular Sequence Data
Monoclonal antibodies
Mutants
Neurology
Peptides
Polymerase chain reaction
Protein Folding
Rapid Communication
Recombinant Proteins - chemistry
Recombinant Proteins - immunology
RNA-directed DNA polymerase
scFv
Tumors of the nervous system. Phacomatoses
Type III deletion mutant
title Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A09%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Production%20of%20a%20Single%E2%80%90chain%20Variable%20Fragment%20Antibody%20Recognizing%20Type%20III%20Mutant%20Epidermal%20Growth%20Factor%20Receptor&rft.jtitle=Cancer%20science&rft.au=Nakayashiki,%20Norihisa&rft.date=2000-10&rft.volume=91&rft.issue=10&rft.spage=1035&rft.epage=1043&rft.pages=1035-1043&rft.issn=0910-5050&rft.eissn=1349-7006&rft.coden=GANNA2&rft_id=info:doi/10.1111/j.1349-7006.2000.tb00882.x&rft_dat=%3Cproquest_pubme%3E72363521%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399579968&rft_id=info:pmid/11050475&rfr_iscdi=true